A new anti-Trump angle on the coronavirus crisis made the front page of Tuesday’s New York Times, raising the silly charge of a financial conflict of interest, questioning Trump’s “motives” for pushing the drug. Excitable Times reporter Ken Vogel: "If hydroxychloroquine becomes an accepted coronavirus treatment, several companies stand to profit, some with shareholders & execs connected to TRUMP. Trump himself has a small interest in @Sanofi, which makes a brand-name hydroxychloroquine version.” A Financial Times journalist who actually looked at Trump...